

(51) International Patent Classification:
A01N 43/40 (2006.01) *A61K 31/44* (2006.01)(21) International Application Number:
PCT/US2010/055691(22) International Filing Date:
5 November 2010 (05.11.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/258,914 6 November 2009 (06.11.2009) US
61/258,918 6 November 2009 (06.11.2009) US(71) Applicant (for all designated States except US): **AKE-BIA THERAPEUTICS INC.** [US/US]; 9987 Carver Road, Suite 420, Cincinnati, OH 45242 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SHALWITZ, Robert** [US/US]; 2549 Bryden Road, Bexley, OH 43209 (US). **GARDNER, Joseph, H.** [US/US]; 4060 Boomer Road, Cincinnati, OH 45247 (US).(74) Agents: **ECHLER, Richard, S.** et al.; 118 Highlands Drive, Woodstock, GA 30188 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA




FIG. 1

(57) Abstract: Disclosed herein are methods for controlling the activity of hypoxia-inducible transcription factor 1- α (HIF- α) and diseases, conditions, or syndromes related thereto, *inter alia*, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia. Further disclosed are pharmaceutical compositions comprising HIF- α prolyl hydroxylase inhibitors useful in treating diseases, conditions, and/or syndromes related thereto the activity of HIF- α .